Convatec has announced a non-discretionary share buyback of up to $300 million to return surplus capital to shareholders. The programme, managed by UBS AG London Branch, will run until 31 December 2025 and aims to reduce the company’s share capital, with purchased shares either cancelled or held in treasury for employee plans...
Convatec Group Plc celebrates the CMS's postponement of LCDs for diabetic foot ulcers, ensuring continued access to their trusted InnovaMatrix® for Medicare patients...
Convatec Group Plc reports robust FY24 results with double-digit growth in EPS and cash flow, driven by strategic execution and expanded product offerings...
Convatec has announced a non-discretionary share buyback of up to $300 million to return surplus capital to shareholders. The programme, managed by UBS AG London Branch, will run until 31 December 2025 and aims to reduce the company’s share capital, with purchased shares either cancelled or held in treasury for employee plans...
Convatec Group Plc celebrates the CMS's postponement of LCDs for diabetic foot ulcers, ensuring continued access to their trusted InnovaMatrix® for Medicare patients...
Convatec Group Plc reports robust FY24 results with double-digit growth in EPS and cash flow, driven by strategic execution and expanded product offerings...
